Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alice Mims

Showing results (11-20 of 49) with videos related to

Pageof 5
Sort By:
The Oncologist|August 12, 2025
Barriers and Facilitators to Representative Acute Leukemia Trial Participation at National Cancer Institute-Designated Comprehensive Cancer CentersAndrew Hantel, Eric C Blackstone, Anna C Revette, et al.
Blood|April 21, 2012
RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemiaJosephine Aimiuwu, Hongyan Wang, Ping Chen, et al.
Leukemia Research|January 15, 2020
Outcomes of the cyclophosphamide, vincristine, prednisone (CVP) +/- rituximab (R-CVP) regimen in older patients with newly diagnosed Ph- acute lymphoblastic leukemiaCaner Saygin, Nicole Grieselhuber, James Blachly, et al.
Journal of Cancer Survivorship : Research and Practice|April 28, 2024
Determining the relationship of p16<sup>INK4a</sup> and additional molecular markers of aging with clinical frailty in hematologic malignancyAshley E Rosko, Mohamed I Elsaid, Jennifer Woyach, et al.
Frontiers in Oncology|January 31, 2022
<i>Post-hoc</i> Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMAJustin Watts, Tara L Lin, Alice Mims, et al.
JAAD Case Reports|May 30, 2023
Cutaneous graft-versus-host disease within chronic photodamaged skin: A case series demonstrating role for topical 5-fluorouracilAshley N Gray, Christina Avila, Catherine G Chung, et al.
Leukemia & Lymphoma|March 28, 2024
Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (m<i>IDH1</i>) acute myeloid leukemia (AML)Jorge Cortes, Brian A Jonas, Gary Schiller, et al.
Leukemia & Lymphoma|February 19, 2019
HSP90 inhibition depletes DNA repair proteins to sensitize acute myelogenous leukemia to nucleoside analog chemotherapeuticsTzung-Huei Lai, Shaneice Mitchell, Pei-Jung Wu, et al.
British Journal of Haematology|December 19, 2024
Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasmStéphane De Botton, Christian Récher, Jorge Cortes, et al.
Molecular and Cellular Biology|April 30, 2014
The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signalingBo Cen, Ying Xiong, Jin H Song, et al.
Pageof 5

Showing results (11-20 of 49) with videos related to

Sort By:
Pageof 5
The Oncologist|August 12, 2025
Barriers and Facilitators to Representative Acute Leukemia Trial Participation at National Cancer Institute-Designated Comprehensive Cancer CentersAndrew Hantel, Eric C Blackstone, Anna C Revette, et al.
Blood|April 21, 2012
RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemiaJosephine Aimiuwu, Hongyan Wang, Ping Chen, et al.
Leukemia Research|January 15, 2020
Outcomes of the cyclophosphamide, vincristine, prednisone (CVP) +/- rituximab (R-CVP) regimen in older patients with newly diagnosed Ph- acute lymphoblastic leukemiaCaner Saygin, Nicole Grieselhuber, James Blachly, et al.
Journal of Cancer Survivorship : Research and Practice|April 28, 2024
Determining the relationship of p16<sup>INK4a</sup> and additional molecular markers of aging with clinical frailty in hematologic malignancyAshley E Rosko, Mohamed I Elsaid, Jennifer Woyach, et al.
Frontiers in Oncology|January 31, 2022
<i>Post-hoc</i> Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMAJustin Watts, Tara L Lin, Alice Mims, et al.
JAAD Case Reports|May 30, 2023
Cutaneous graft-versus-host disease within chronic photodamaged skin: A case series demonstrating role for topical 5-fluorouracilAshley N Gray, Christina Avila, Catherine G Chung, et al.
Leukemia & Lymphoma|March 28, 2024
Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (m<i>IDH1</i>) acute myeloid leukemia (AML)Jorge Cortes, Brian A Jonas, Gary Schiller, et al.
Leukemia & Lymphoma|February 19, 2019
HSP90 inhibition depletes DNA repair proteins to sensitize acute myelogenous leukemia to nucleoside analog chemotherapeuticsTzung-Huei Lai, Shaneice Mitchell, Pei-Jung Wu, et al.
British Journal of Haematology|December 19, 2024
Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasmStéphane De Botton, Christian Récher, Jorge Cortes, et al.
Molecular and Cellular Biology|April 30, 2014
The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signalingBo Cen, Ying Xiong, Jin H Song, et al.
Pageof 5